Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry M Brenner

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Fetal programming of adult kidney disease: cellular and molecular mechanismsDov Hershkovitz, Zvi Burbea, Karl Skorecki, et al.
Hypertension (Dallas, Tex. : 1979)|January 18, 2006
Adult hypertension and kidney disease: the role of fetal programmingKambiz Zandi-Nejad, Valerie A Luyckx, Barry M Brenner
The New England Journal of Medicine|March 15, 2013
Aliskiren in type 2 diabetes and cardiorenal end pointsMarc A Pfeffer, Barry M Brenner, John J V McMurray
Current Opinion in Nephrology and Hypertension|October 6, 2023
Climate change and its influence in nephron massAna Catalina Alvarez-Elias, Barry M Brenner, Valerie A Luyckx
Kidney International|March 13, 2003
Dialysis delayed is death prevented: a clinical perspective on the RENAAL studyMerlin C Thomas, Mark E Cooper, Shahnaz Shahinfar, et al.
Kidney International. Supplement|January 25, 2005
Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL StudyShahnaz Shahinfar, Tanya Dickson, Zhongxin Zhang, et al.
Kidney International. Supplement|October 16, 2004
Why is proteinuria an ominous biomarker of progressive kidney disease?Kambiz Zandi-Nejad, Allison A Eddy, Richard J Glassock, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 19, 2009
Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severityDavid G Warnock, Giuseppe Remuzzi, Barry M Brenner, et al.
Clinical Cardiology|April 9, 2005
Losartan and end-organ protection--lessons from the RENAAL studyPeter R Kowey, Tania Z Dickson, Zhongxin Zhang, et al.
Expert Opinion on Pharmacotherapy|March 24, 2006
Losartan: lessons learned from the RENAAL studyShahnaz Shahinfar, Paulette A Lyle, Zhongxin Zhang, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Fetal programming of adult kidney disease: cellular and molecular mechanismsDov Hershkovitz, Zvi Burbea, Karl Skorecki, et al.
Hypertension (Dallas, Tex. : 1979)|January 18, 2006
Adult hypertension and kidney disease: the role of fetal programmingKambiz Zandi-Nejad, Valerie A Luyckx, Barry M Brenner
The New England Journal of Medicine|March 15, 2013
Aliskiren in type 2 diabetes and cardiorenal end pointsMarc A Pfeffer, Barry M Brenner, John J V McMurray
Current Opinion in Nephrology and Hypertension|October 6, 2023
Climate change and its influence in nephron massAna Catalina Alvarez-Elias, Barry M Brenner, Valerie A Luyckx
Kidney International|March 13, 2003
Dialysis delayed is death prevented: a clinical perspective on the RENAAL studyMerlin C Thomas, Mark E Cooper, Shahnaz Shahinfar, et al.
Kidney International. Supplement|January 25, 2005
Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL StudyShahnaz Shahinfar, Tanya Dickson, Zhongxin Zhang, et al.
Kidney International. Supplement|October 16, 2004
Why is proteinuria an ominous biomarker of progressive kidney disease?Kambiz Zandi-Nejad, Allison A Eddy, Richard J Glassock, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 19, 2009
Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severityDavid G Warnock, Giuseppe Remuzzi, Barry M Brenner, et al.
Clinical Cardiology|April 9, 2005
Losartan and end-organ protection--lessons from the RENAAL studyPeter R Kowey, Tania Z Dickson, Zhongxin Zhang, et al.
Expert Opinion on Pharmacotherapy|March 24, 2006
Losartan: lessons learned from the RENAAL studyShahnaz Shahinfar, Paulette A Lyle, Zhongxin Zhang, et al.
Pageof 7